It is likely that patients who are rarely in the therapeutic range receive little or no benefit from treatment with VKAs. Indeed, several reports have indicated an association between low TTR and increased rates of both stroke/SE and major hemorrhage in patients on VKAs. Interestingly, secondary analyses of the RCTs of DOACs indicate that warfarin at TTR $70% has comparable efficacy and safety to those of novel anticoagulants (5-7). Therefore, it has become a common belief that patients with good
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anticoagulation control on warfarin, as expressed by a TTR $70%, derive little or no benefit at all from switching to a DOAC, a concept that has been endorsed by current guidelines, which recommend maintaining patients on VKAs when TTR is $70% (1).
This, however, assumes that TTR will remain stably high over time, but only limited data on this topic exist in the published reports (8, 9) .
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